Speciality drugmaker Alliance Pharma has agreed to be taken private in a deal valued at more than £360.0m.
Source: Sharecast
DBAY Advisors, which holds a 27% stake in Alliance Pharma, has upped its initial bid for the firm by 2.25p per share to 64.75p, a deal which has been recommended by Alliance's board.
DBAY's new offer represents a 41% premium to Alliance's closing price on 9 January and a 121% premium to the AIM-listed group's share price when DBAY first registered its interest in a potential takeover back in May last year.
Alliance executives cited a lack of access to funding as its primary reason for choosing to take the firm private.
As of 1000 GMT, Alliance Pharma shares were up 2.32% at 63.95p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
